Another observational cohort study (2010–2015), which included data from DANBIO and the Anti-Rheumatic Treatment in Sweden Register/Swedish Rheumatology Quality Register, investigated the risk of serious (hospitalized) infections in patients with RA who started treatment with non-tumour necrosis factor (TNF) inhibitor bDMARDs [36]. This evidence concerns the gene TNF and infection.